Sionna Therapeutics, Inc. 8-K

What Happened
Sionna Therapeutics, Inc. filed an 8-K reporting the results of its Annual Meeting of Stockholders held on June 17, 2026 (record date April 21, 2026). A quorum was present. There were 45,142,330 shares of common stock outstanding as of the record date. Four Class II director nominees — H. Edward Fleming, Jr., M.D.; Marcella Kuhlman Ruddy, M.D.; Peter A. Thompson, M.D.; and Joanne Louise Viney, Ph.D. — were elected. The appointment of Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified.

Key Details

• Shares outstanding (record date April 21, 2026): 45,142,330.
• Director vote totals (Votes For / Votes Withheld / Broker Non-Votes):
  • H. Edward Fleming, Jr.: 42,168,569 / 40,021 / 1,084,330
  • Marcella Kuhlman Ruddy: 40,270,279 / 1,938,311 / 1,084,330
  • Peter A. Thompson: 39,862,185 / 2,346,405 / 1,084,330
  • Joanne Louise Viney: 41,931,706 / 276,884 / 1,084,330
• Auditor ratification vote: 43,291,215 for, 1,198 against, 507 abstentions.
• The proxy materials describing these proposals were filed April 27, 2026.

Why It Matters
These votes confirm the company’s board composition and auditor for 2026, which affect governance and financial oversight. For investors, the results indicate shareholder support for the nominated directors and for retaining Deloitte & Touche as Sionna’s independent auditor, reducing near-term governance uncertainty.